Hypertrophic Cardiomyopathy Is at Increased Risk of Thromboembolic Events: Deficiencies of CHA(2)DS(2)-VASC Score and How to Predict

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F19%3A10402050" target="_blank" >RIV/00064203:_____/19:10402050 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/19:10402050

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=TZ7Cc78jlB" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=TZ7Cc78jlB</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cjca.2019.07.004" target="_blank" >10.1016/j.cjca.2019.07.004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hypertrophic Cardiomyopathy Is at Increased Risk of Thromboembolic Events: Deficiencies of CHA(2)DS(2)-VASC Score and How to Predict

Popis výsledku v původním jazyce

Patients with hypertrophic cardiomyopathy (HCM) are at increased risk of potentially catastrophic thromboembolic (TE) events that can occur without any previous clinical symptoms. Recently, the Hypertrophic Cardiomyopathy Outcome Investigators developed a model to predict TE risk in patients with HCM (HCM Risk-CVA model). In this issue of the Canadian Journal of Cardiology, He et al. describe the first external validation of the previously developed HCM Risk-CVA model for the long-term TE risk. They collected 417 patients with HCM and followed them for 3.5 years. Six percent of the patients experienced a TE end point, and the model demonstrated modest, but nevertheless potentially useful, discriminating capacity for TE events (C-index 0.67). Therefore, the authors suggest using it in clinical practice for individual prognosis and antithrombotic management.

Název v anglickém jazyce

Hypertrophic Cardiomyopathy Is at Increased Risk of Thromboembolic Events: Deficiencies of CHA(2)DS(2)-VASC Score and How to Predict

Popis výsledku anglicky

Patients with hypertrophic cardiomyopathy (HCM) are at increased risk of potentially catastrophic thromboembolic (TE) events that can occur without any previous clinical symptoms. Recently, the Hypertrophic Cardiomyopathy Outcome Investigators developed a model to predict TE risk in patients with HCM (HCM Risk-CVA model). In this issue of the Canadian Journal of Cardiology, He et al. describe the first external validation of the previously developed HCM Risk-CVA model for the long-term TE risk. They collected 417 patients with HCM and followed them for 3.5 years. Six percent of the patients experienced a TE end point, and the model demonstrated modest, but nevertheless potentially useful, discriminating capacity for TE events (C-index 0.67). Therefore, the authors suggest using it in clinical practice for individual prognosis and antithrombotic management.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů